Table of Contents
Chromatography Research International
Volume 2012, Article ID 437075, 11 pages
http://dx.doi.org/10.1155/2012/437075
Research Article

Pharmacokinetics of Single-Dose and Multi-Dose of Lovastatin/Niacin ER Tablet in Healthy Volunteers

Department of Pharmacy, Xijing Hospital of the Fourth Military Medical University, Xi’an 710032, China

Received 22 November 2011; Revised 21 February 2012; Accepted 28 February 2012

Academic Editor: Meehir Palit

Copyright © 2012 Yan-yan Jia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. P. Song, P. P. Chen, and X. S. Chai, “Effects of puerarin on blood pressure and plasma renin activity in spontaneously hypertensive rats,” Acta Pharmacologica Sinica, vol. 9, no. 1, pp. 55–58, 1988. View at Google Scholar · View at Scopus
  2. V. S. Kamanna and M. L. Kashyap, “Nicotinic acid (Niacin) receptor agonists: will they be useful therapeutic agents?” American Journal of Cardiology, vol. 100, no. 11, pp. S53–S61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. M. Menon, M. A. González, M. H. Adams, D. S. Tolbert, J. H. Leu, and E. A. Cefali, “Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites,” Journal of Clinical Pharmacology, vol. 47, no. 6, pp. 681–688, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Avisar, J. G. Brook, and E. Wolfovitz, “Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia,” European Journal of Internal Medicine, vol. 19, no. 3, pp. 203–208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Kashyap, M. E. McGovern, K. Berra et al., “Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia,” American Journal of Cardiology, vol. 89, no. 6, pp. 672–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. LaFleur, C. J. Thompson, V. N. Joish, S. L. Charland, G. M. Oderda, and D. I. Brixner, “Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin,” Annals of Pharmacotherapy, vol. 40, no. 7-8, pp. 1274–1279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. H. E. Bays, “Extended-release niacin/lovastatin: the first combination product for dyslipidemia,” Expert Review of Cardiovascular Therapy, vol. 2, no. 4, pp. 485–501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Shitara and Y. Sugiyama, “Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions,” Pharmacology and Therapeutics, vol. 112, no. 1, pp. 71–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. E. Gaudineau and K. Auclair, “Inhibition of human P450 enzymes by nicotinic acid and nicotinamide,” Biochemical and Biophysical Research Communications, vol. 317, no. 3, pp. 950–956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. F. Solus, B. J. Arietta, J. R. Harris et al., “Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population,” Pharmacogenomics, vol. 5, no. 7, pp. 895–931, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Oliveira, S. Marsh, D. J. van Booven, A. Amorim, M. J. Prata, and H. L. McLeod, “Pharmacogenetically relevant polymorphisms in Portugal,” Pharmacogenomics, vol. 8, no. 7, pp. 703–712, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. M. Menon, D. Tolbert, and E. Cefali, “The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet,” Biopharmaceutics and Drug Disposition, vol. 28, no. 6, pp. 297–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. A. Alsheikh-Ali and R. H. Karas, “Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system),” American Journal of Cardiology, vol. 99, no. 3, pp. 379–381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Sharma, D. R. Sharma, V. Singh et al., “Evaluation of efficacy and safety of fixed dose lovastatin and niacinER combination in Asian Indian dyslipidemic patients: a multicentric study,” Vascular Health and Risk Management, vol. 2, no. 1, pp. 87–93, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Insull Jr., M. E. McGovern, H. Schrott et al., “Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis,” Archives of Internal Medicine, vol. 164, no. 10, pp. 1121–1127, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Pfuhl, U. Kärcher, N. Häring, A. Baumeister, M. A. Tawab, and M. Schubert-Zsilavecz, “Simultaneous determination of niacin, niacinamide and nicotinuric acid in human plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 5, pp. 1045–1052, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. X. Sun, R. Niecestro, G. Phillips, J. Shen, P. Lukacsko, and L. Friedhoff, “Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans,” Journal of Clinical Pharmacology, vol. 42, no. 2, pp. 198–204, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Mignini, D. Tomassoni, V. Streccioni, E. Traini, and F. Amenta, “Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers,” Clinical and Experimental Hypertension, vol. 30, no. 2, pp. 95–108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Hamidi, N. Zarei, and M. A. Shahbazi, “A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: application to a bioequivalence study,” Biological and Pharmaceutical Bulletin, vol. 32, no. 9, pp. 1600–1603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Mullangi and N. R. Srinivas, “Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview,” Biomedical Chromatography, vol. 25, no. 1, pp. 218–237, 2011. View at Publisher · View at Google Scholar · View at Scopus